In December 2023, the U.S. Department of Health and Human Services, in collaboration with the Food and Drug Administration (FDA), released a groundbreaking guidance document titled “Data Standards for Drug and Biological Product Submissions Containing Real-World Data.” This guidance is a crucial milestone in the evolving landscape of medical product development, specifically addressing the integration […]

In the ever-evolving field of healthcare, bringing a new medicine to market is a complex and highly regulated process. For pharmaceutical companies and individuals alike, understanding the intricacies of obtaining a license to market a medicine in the United Kingdom is crucial. Fortunately, the UK government provides a comprehensive guide to streamline this process, ensuring

The life sciences landscape is a bustling hub, constantly buzzing with innovation and adaptation. But staying ahead of the curve also means navigating a complex web of regulations. To help you chart your course, let’s dive into some crucial updates impacting medical devices, clinical trials, and drug approvals: EU Medical Devices Regulation (EU MDR): High-stakes

In the dynamic world of pharmaceuticals, staying ahead of regulatory changes is crucial for life sciences professionals, particularly those involved in Abbreviated New Drug Applications (ANDAs). The Food and Drug Administration’s (FDA) recent guidance on “Revising ANDA Labeling Following Revision of the RLD Labeling” presents both opportunities and challenges. This blog serves as a roadmap,